Lucía Figueroa-Protti

Prof. Lucía Figueroa-Protti

Universidad de Costa Rica
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
José María GutiérrezJosé María Gutiérrez
José María Gutiérrez
LSLibia Sanz
Libia Sanz
MFMarietta Flores-Díaz
Marietta Flores-Díaz
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
MMMarvin Madrigal
Marvin Madrigal
JCJuan Calvete
Juan Calvete

24 September 2019 in Journal of Oncology
Verified
Journal Article
Open access
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
RSRebeca Soto-Molinari
Rebeca Soto-Molinari
MCMelany Calderón-Osorno
Melany Calderón-Osorno
JMJavier Mora
Javier Mora
Warner Alpízar-AlpízarWarner Alpízar-Alpízar
Warner Alpízar-Alpízar
Gastric cancer (GC) is one of the most important malignancies worldwide because of its high incidence and mortality. The very low survival rates are mainly related to late diagnosis and limited treatment options. GC is the final clinical outcome of a stepwise process that starts with a chronic and sustained inflammatory reaction mounted in response toHelicobacter pyloriinfection. The bacterium modulates innate and adaptive immunity presumably as part of the strategies to survive, which favors the creation of an immunosuppressive microenvironment that ultimately facilitates GC progression. T-cell exhaustion, which is characterized by elevated expression of immune checkpoint (IC) proteins, is one of the most salient manifestations of immunosuppressive microenvironments. It has been consistently demonstrated that the tumor-immune microenvironment(TIME)‐exhausted phenotype can be reverted by blocking ICs with monoclonal antibodies. Although these therapies are associated with long-lasting response rates, only a subset of patients derive clinical benefit, which varies according to tumor site. The search for biomarkers to predict the response to IC inhibition is a matter of intense investigation as this may contribute to maximize disease control, reduce side effects, and minimize cost. The approval of pembrolizumab for its use in GC has rocketed immuno-oncology research in this cancer type. In this review, we summarize the current knowledge centered around the immune contexture and recent findings in connection with IC inhibition in GC.

15 February 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
WMWendy Malespín-Bendaña
Wendy Malespín-Bendaña
WAWarner Alpízar-Alpízar
Warner Alpízar-Alpízar
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
LRLedis Reyes
Ledis Reyes
SMSilvia Molina-Castro
Silvia Molina-Castro
VRVanessa Ramírez-Mayorga
Vanessa Ramírez-Mayorga
Introduction: Helicobacter pylori colonizes the gastric mucosa and induces chronic inflammation. Methods: Using a mouse model of H. pylori-induced gastritis, we evaluated the mRNA and protein expression levels of proinflammatory and proangiogenic factors, as well as the histopathological changes in gastric mucosa in response to infection. Five- to six-week-old female C57BL/6N mice were challenged with H. pylori SS1 strain. Animals were euthanized after 5-, 10-, 20-, 30-, 40- and 50-weeks post infection. mRNA and protein expression of Angpt1, Angpt2, VegfA, Tnf-α, bacterial colonization, inflammatory response and gastric lesions were evaluated. Results: A robust bacterial colonization was observed in 30 to 50 weeks-infected mice, which was accompanied by immune cell infiltration in the gastric mucosa. Compared to non-infected animals, H. pylori-colonized animals showed an upregulation in the expression of Tnf-A, Angpt2 and VegfA at the mRNA and protein levels. In contrast, Angpt1 mRNA and protein expression was downregulated in H. pylori-colonized mice. Conclusion: Our data show that H. pylori infection induces the expression of Angpt2, Tnf-A and Vegf-A in murine gastric epithelium. This may contribute to the pathogenesis of H. pylori-associated gastritis, however the significance of this should be further addressed.

20 September 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
ACAna Cristina Castro-Castro
Ana Cristina Castro-Castro
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
JMJose Arturo Molina-Mora
Jose Arturo Molina-Mora
MRMaría Paula Rojas-Salas
María Paula Rojas-Salas
DVDanae Villafuerte-Mena
Danae Villafuerte-Mena
JMJavier Mora
Javier Mora
COVID-19 is a disease caused by the novel Coronavirus SARS-CoV-2 causing an acute respiratory disease that can eventually lead to severe acute respiratory syndrome (SARS). An exacerbated inflammatory response is characteristic of SARS-CoV-2 infection, which leads to a cytokine release syndrome also known as cytokine storm associated with the severity of the disease. Considering the importance of this event in the immunopathology of COVID-19, this study analyses cytokine levels of hospitalized patients to identify cytokine profiles associated with severity and mortality. Using a machine learning approach, 3 clusters of COVID-19 hospitalized patients were created based on their cytokine profile. Significant differences in the mortality rate were found among the clusters, associated to different CXCL10/IL-38 ratio. The balance of a CXCL10 induced inflammation with an appropriate immune regulation mediated by the anti-inflammatory cytokine IL-38 appears to generate the adequate immune context to overrule SARS-CoV-2 infection without creating a harmful inflammatory reaction. This study supports the concept that analyzing a single cytokine is insufficient to determine the outcome of a complex disease such as COVID-19, and different strategies incorporating bioinformatic analyses considering a broader immune profile represent a more robust alternative to predict the outcome of hospitalized patients with SARS-CoV-2 infection.

6 March 2023 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
WMWendy Malespín-Bendaña
Wendy Malespín-Bendaña
RFRui M. Ferreira
Rui M. Ferreira
MPMarta T. Pinto
Marta T. Pinto
CFCeu Figueiredo
Ceu Figueiredo
WAWarner Alpízar-Alpízar
Warner Alpízar-Alpízar
VRVanessa Ramírez
Vanessa Ramírez

18 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
IQIsaac Quiros-Fernandez
Isaac Quiros-Fernandez
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
Jorge L. Arias-AriasJorge L. Arias-Arias
Jorge L. Arias-Arias
Norman Brenes-CorderoNorman Brenes-Cordero
Norman Brenes-Cordero
FCFrancisco Siles Canales
Francisco Siles Canales
RMRodrigo Mora
Rodrigo Mora
In the absence of new therapeutic strategies, chemotherapeutic drugs are the most widely used strategy against metastatic breast cancer, in spite of eliciting multiple adverse effects and having low responses with an average 5-year patient survival rate. Among the new therapeutic targets that are currently in clinical trials, here, we addressed the association between the regulation of the metabolic process of autophagy and the exposure of damage-associated molecular patterns associated (DAMPs) to immunogenic cell death (ICD), which has not been previously studied. After validating an mCHR-GFP tandem LC3 sensor capacity to report dynamic changes of the autophagic metabolic flux in response to external stimuli and demonstrating that both basal autophagy levels and response to diverse autophagy regulators fluctuate among different cell lines, we explored the interaction between autophagy modulators and chemotherapeutic agents in regards of cytotoxicity and ICD using three different breast cancer cell lines. Since these interactions are very complex and variable throughout different cell lines, we designed a perturbation-based model in which we propose specific modes of action of chemotherapeutic agents on the autophagic flux and the corresponding strategies of modulation to enhance the response to chemotherapy. Our results point towards a promising therapeutic potential of the metabolic regulation of autophagy to overcome chemotherapy resistance by eliciting ICD.